Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Ipsen and Dicerna to collaborate on endocrinology and oncology research

Ipsen and Dicerna to collaborate on endocrinology and oncology research

30th March 2010

Ipsen has entered into a research collaboration with Dicerna Pharmaceuticals which will see the two firms pool their expertise to develop new endocrinology and oncology agents.

Dicerna’s Dicer Substrate siRNA (DsiRNA) technology and molecules will be employed alongside Ipsen’s peptide targeting vectors to help silence disease-causing genes.

This technique will allow for the development of therapeutic options which combat disease in a highly selective and specific way.

Both firms are also considering continuing to work together to develop discoveries made under this programme into commercial prospects.

Claude Bertrand, executive vice-president and chief scientific officer for Ipsen, said: “We believe that this collaboration brings together two leading companies with unique and complementary technology platforms which could potentially lead to the discovery of breakthrough DsiRNA-based therapies.”

Last week, Ipsen announced an expansion of its partnership with biopharmaceutical company GTx to gain a wider range of commercial and marketing rights to the jointly-developed prostate cancer drug toremifene.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.